Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

In this article, we are going to take a look at where FormFactor, Inc. (NASDAQ:FORM) stands against the other AI stocks. The evolving space of AI has been a major focus these days, as experts and ...

So, when comparing Netflix Standard vs Premium, which is right for you? Below, we break down the pros and cons of the two pricier options. If you’re ready to sign up, you can do so by hitting ...

While it wasn’t found to be superior to that standard therapy for acute pain in both trials, Vertex’s drug offers ... mainly around nerve growth factor inhibitors, but the two leaders in ...

PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") is pleased to announce its fourth quarter and year-end operating and financial results for the period ended December 31, 2024. PrairieSky is ...

Royalty Pharma Plc (RPRX) reported its Q4 2024 earnings today, revealing earnings per share (EPS) of $0.3531, falling short of the forecasted $0.9849. The company also reported revenue of $594 million ...